SA
GH icon

Sicart Associates’s Guardant Health GH Stock Holding History

Sicart Associates’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.3M Buy
230,103
+1,900
+0.8% +$191K 5.46% 3
2025
Q4 		$23.3M Sell
228,203
-1,880
-0.8% -$168K 6.18% 3
2025
Q3 		$14.4M Buy
230,083
+64,628
+39% +$3.52M 3.89% 5
2025
Q2 		$8.61M Buy
165,455
+27,862
+20% +$1.24M 3.01% 11
2025
Q1 		$5.86M Sell
137,593
-2,740
-2% -$118K 2.03% 20
2024
Q4 		$4.29M Sell
140,333
-5,970
-4% -$168K 1.53% 28
2024
Q3 		$3.36M Buy
146,303
+320
+0.2% +$9.06K 1.18% 33
2024
Q2 		$4.22M Sell
145,983
-609
-0.4% -$14.2K 1.62% 28
2024
Q1 		$3.02M Buy
146,592
+53,639
+58% +$1.15M 1.11% 30
2023
Q4 		$2.51M Sell
92,953
-2,972
-3% -$78K 0.96% 34
2023
Q3 		$2.84M Buy
95,925
+2,955
+3% +$104K 1.12% 32
2023
Q2 		$3.33M Buy
92,970
+3,050
+3% +$87.6K 1.29% 30
2023
Q1 		$2.11M Sell
89,920
-8,070
-8% -$230K 0.82% 35
2022
Q4 		$2.67M Sell
97,990
-38,469
-28% -$1.76M 0.94% 33
2022
Q3 		$7.35M Sell
136,459
-1,430
-1% -$73.4K 2.61% 15
2022
Q2 		$5.56M Buy
137,889
+4,223
+3% +$209K 1.73% 24
2022
Q1 		$8.85M Buy
133,666
+91,783
+219% +$6.28M 2.29% 17
2021
Q4 		$4.2M Buy
41,883
+41
+0.1% +$4.24K 1.1% 29
2021
Q3 		$5.23M Buy
41,842
+1,322
+3% +$157K 1.43% 23
2021
Q2 		$5.03M Buy
+40,520
New +$5.45M 1.2% 31

Other funds holding GH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sicart Associates's GH Position: Q1 2026 in Review

Sicart Associates increased its Guardant Health (GH) stake by 0.83% in Q1 2026, buying an estimated $191K and bringing the position to 230,103 shares worth $21.3M. The position accounts for 5.46% of the portfolio, ranked #3.

Sicart Associates first reported a position in GH in Q2 2021 and has held it in 20 quarters since. The position peaked at $23.3M in Q4 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • Sicart Associates held 230,103 shares of Guardant Health worth $21.3M as of Q1 2026.
  • Sicart Associates bought 1,900 Guardant Health shares in Q1 2026, an estimated $191K.
  • Guardant Health made up 5.46% of Sicart Associates's portfolio in Q1 2026, its #3 holding.
  • Sicart Associates first reported a position in Guardant Health in Q2 2021 and has held it in 20 quarters since.
  • Sicart Associates's Guardant Health position peaked at $23.3M in Q4 2025.
  • 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Sicart Associates's 13F filing for Q1 2026, filed 21 Apr 2026.